EU research funding aids scientific excellence, competitiveness - report

25 January 2016
eu-european-union-flag

Investment in research and innovation from the European Union budget between 2007 and 2013 has greatly improved scientific excellence in Europe and strengthened its competitiveness by improving industry's capacity to innovate, according to findings of evaluation of EU's 7th Framework Program (FP7) published today by the European Commission.

Carlos Moedas, Commissioner for Research, Science and Innovation, said: "Independent experts have confirmed that our research and innovation investments are supporting world class science and improving our citizen's welfare. We are now using the lessons learned to further improve Horizon 2020, the new EU research and innovation funding programme, and make it simpler, more effective and more focused on finding innovative solutions to benefit our society and economy."

The ex-post evaluation of the 7th Framework Program shows that the 55 billion euros ($59.5 billion) invested over seven years into EU's research and innovation proved highly attractive to private sector participants, including a record number of SMEs, which helped strengthen competitiveness of European industries. The program also set up five Joint Technology Initiatives in key areas like innovative medicine and hydrogen and fuel cells.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical